Prot #D926XC00001: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-Negative Breast Cancer Who Have Residual Invasive Disease

Project: Research project

Project Details

StatusActive
Effective start/end date1/25/24 → 1/25/27

Funding

  • AstraZeneca Pharmaceuticals LP (Prot #D926XC00001)